NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
541 Värmland

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 480 7.2% 270 4.1% 13 0.2% . . 4 0.1% 26 0.4% 5834 88.0% 6627 100.0%
ASCUS 191 22.3% 287 33.6% 73 8.5% 1 0.1% 4 0.5% 14 1.6% 285 33.3% 855 100.0%
LSIL 155 18.5% 359 42.8% 108 12.9% 1 0.1% . . 7 0.8% 208 24.8% 838 100.0%
Atypical glandular cells/AGC 9 29.0% 6 19.4% 6 19.4% 5 16.1% 2 6.5% 1 3.2% 2 6.5% 31 100.0%
Unclear atypia 1 33.3% . . 1 33.3% . . . . . . 1 33.3% 3 100.0%
ASC-H 6 9.5% 26 41.3% 26 41.3% 2 3.2% . . . . 3 4.8% 63 100.0%
HSIL 9 4.1% 24 11.0% 175 80.3% 1 0.5% 6 2.8% . . 3 1.4% 218 100.0%
Suspected Adenocarcinom 2 16.7% . . . . 4 33.3% 2 16.7% . . 4 33.3% 12 100.0%
Squamous cell cancer . . . . 2 66.7% . . 1 33.3% . . . . 3 100.0%
Totalt 853 9.9% 972 11.2% 404 4.7% 14 0.2% 19 0.2% 48 0.6% 6340 73.3% 8650 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category Cancer:
M80109, M80703, M81403, M83803